Amylyx Pharmaceuticals, Inc.

What they do

Amylyx is developing novel therapies for endocrine and neurodegenerative diseases. Its lead candidate, avexitide, a GLP-1 receptor antagonist, is in Phase 3 for post-bariatric hypoglycemia (PBH) and has FDA Breakthrough Therapy Designation. The pipeline also includes AMX0035 for Wolfram syndrome, AMX0114 for ALS, and AMX0318 for PBH and other rare diseases.

Revenue drivers

• Avexitide — Lead investigational therapy for PBH and congenital hyperinsulinemia; no approved product or revenue yet, but potential commercial launch in 2027 if approved.
• AMX0035 — In clinical development for Wolfram syndrome, a rare genetic disease; no revenue generated from this candidate.
• AMX0114 — Antisense oligonucleotide for ALS; early-stage (Phase 1) with no revenue; data supported continued dose escalation.

Recent performance

Amylyx reported zero revenue for 2025 and all quarters of 2025, reflecting the cessation of its previous ALS product. Net loss for 2025 was $144.7 million, with operating cash flow of -$123.3 million. As of June 30, 2026, cash and equivalents were $49.3 million, with total assets of $264.6 million and shareholder equity of $239.2 million.

Strategy

Management is prioritizing the late-stage development of avexitide, with LUCIDITY Phase 3 topline data expected in late August or early September 2026. They are advancing NDA readiness and pre-commercial activities to support a potential 2027 launch. They also initiated a U.S. Expanded Access Program for avexitide and are building disease-state awareness through an education campaign. Additional pipeline work includes partnerships, such as a research collaboration with Gubra A/S for a rare endocrine disease.

Risks

• Dependence on avexitide — If LUCIDITY fails or regulatory approval is delayed, the company's business could be materially harmed.
• No revenue and ongoing losses — The company has zero revenue and expects significant losses until a product is commercialized.
• Capital needs — The company may require substantial additional funding to continue operations beyond its current cash runway into 2028.
• Clinical trial and regulatory risks — Delays or failures in late-stage trials or regulatory approvals for any candidate could harm the business.

Outlook

Management expects to announce topline data from the Phase 3 LUCIDITY trial in late August or early September 2026, with a potential commercial launch of avexitide in 2027 if approved. Cash runway is projected to fund operations into 2028. They continue to advance the pipeline, including AMX0114 and AMX0035, with additional data presentations planned.